Results 251 to 260 of about 338,185 (301)

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

Assessing the Impact of Colchicine on Pulmonary Fibrosis Using Imaging in Patients With Moderate-to-Severe COVID-19 Pneumonia. [PDF]

Can Respir J
Ayhan Albayrak G, Bardakci MI, Temel U.
europepmc   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola, Aleksandar Gigov, Hubertus G. M. Leufkens, Andrew Bate, Marie Louise De Bruin, Helga Gardarsdottir   +5 more
wiley   +1 more source

Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency's Response to the Pandemic. [PDF]

Pharmacy (Basel)
Ivanov A, Getova-Kolarova V, Hababa-Ivanova I.   +2 more
europepmc   +1 more source

Scoping review about pathogenesis, risk factors, and treatment of venous and arterial thrombosis in coronavirus infection. [PDF]

Front Cardiovasc Med
Malaeb D, Mansour S, Dia N, Kassem NM, Haddad C, Dabbous M, Ismail O, Adel F, Gamal M, Lucca JM, El Khatib S, Salameh P, Hallit S, Hosseini H.   +13 more
europepmc   +1 more source

Lost learning: Prevalence, inequalities and outcomes of internal exclusion in mainstream secondary schools

British Educational Research Journal, EarlyView.
Abstract Internal exclusion (isolation) is a behaviour management approach involving the temporary relocation of a pupil from their classroom to a designated isolation space as a consequence of disruptive behaviour. We present the first study of prevalence (i.e., what proportion of young people are isolated?), inequalities (i.e., who is more likely to ...
Emma Thornton, Qiqi Cheng, Ola Demkowicz, Neil Humphrey   +3 more
wiley   +1 more source

Rapid establishment of public sector COVID-19 test-and-treatment programmes across seven low- and middle-income countries: implementation strategies and program monitoring results. [PDF]

BMJ Glob Health
Boeke CE, Hamza N, Agwuocha C, Amako O, Detleuxay K, Gao M, Griffith BC, Gumulira Y, Urli Hodges E, Joseph J, Lufesi N, Macharia E, Mbewe N, McCarthy E, Mintah FO, Mukiibi M, Mulenga M, Ngwije A, Ofori-Boadu L, Okoli IU, Phongphila S, Ramers C, Regan S, Twinomujuni E, Rwagasore E, Tebor J, Udayakumar K, COVID-19 Treatment QuickStart Consortium.   +27 more
europepmc   +1 more source

Coinfection of SARS-CoV-2 and Influenza: A Catastrophic Coexistence. [PDF]

Infect Drug Resist
Jheng CY, Wang NC, Wang YC.
europepmc   +1 more source